Funds and ETFs Cerevel Therapeutics Holdings, Inc.




Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
42.21 USD +0.17% Intraday chart for Cerevel Therapeutics Holdings, Inc. +0.86% -0.45%

ETFs positioned on Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.
Related indices
More about the company
Mean consensus
Number of Analysts
Last Close Price
42.21 USD
Average target price
44.78 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. CERE Stock
  4. Funds and ETFs Cerevel Therapeutics Holdings, Inc.